4-(7-CHLORO-QUINOLIN-4-YLAMINO)-2-MORPHOLIN-4-YLMETHYL-PHENOL

/static/temp/default.svg

Search structure


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	ORZXMSZHPHCTBO-UHFFFAOYSA-N
Smiles	Oc1ccc(Nc2ccnc3cc(Cl)ccc23)cc1CN4CCOCC4
InChI	InChI=1S/C20H20ClN3O2/c21-15-1-3-17-18(5-6-22-19(17)12-15)23-16-2-4-20(25)14(11-16)13-24-7-9-26-10-8-24/h1-6,11-12,25H,7-10,13H2,(H,22,23)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C20H20ClN3O2
Molecular Weight	369.84
AlogP	3.75
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	4.0
Polar Surface Area	57.62
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	26.0

Assay Description	Organism	Bioactivity	Reference
Antimalarial activity against chloroquine-resistant Plasmodium yoelii infected Swiss mouse assessed as mouse showing nil parasitemia at 500 mg/kg, po qd for 4 days measured on day 4	Plasmodium yoelii	None
Antimalarial activity against chloroquine-resistant Plasmodium yoelii infected Swiss mouse assessed as mouse showing nil parasitemia at 500 mg/kg, po qd for 4 days measured on day 10	Plasmodium yoelii	None
Antimalarial activity against chloroquine-resistant Plasmodium yoelii infected Swiss mouse assessed as mouse showing nil parasitemia at 500 mg/kg, po qd for 4 days measured on day 7	Plasmodium yoelii	None
Antimalarial activity against chloroquine-resistant Plasmodium yoelii infected Swiss mouse assessed as suppression parasitemia at 500 mg/kg, po qd for 4 days	Plasmodium yoelii	100.0 %
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of schizont maturation at 0.031 ug/ml after 36 to 40 hr incubation by Giemsa staining	Plasmodium falciparum 3D7	73.33 %
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of schizont maturation at 0.063 ug/ml after 36 to 40 hr incubation by Giemsa staining	Plasmodium falciparum 3D7	100.0 %
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of schizont maturation at 0.125 ug/ml after 36 to 40 hr incubation by Giemsa staining	Plasmodium falciparum 3D7	100.0 %
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of schizont maturation at 0.25 ug/ml after 36 to 40 hr incubation by Giemsa staining	Plasmodium falciparum 3D7	100.0 %
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of schizont maturation at 0.5 ug/ml after 36 to 40 hr incubation by Giemsa staining	Plasmodium falciparum 3D7	100.0 %
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of schizont maturation at 1 ug/ml after 36 to 40 hr incubation by Giemsa staining	Plasmodium falciparum 3D7	100.0 %
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of schizont maturation at 2 ug/ml after 36 to 40 hr incubation by Giemsa staining	Plasmodium falciparum 3D7	100.0 %
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of schizont maturation at 10 ug/ml after 36 to 40 hr incubation by Giemsa staining	Plasmodium falciparum 3D7	100.0 %
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of schizont maturation at 100 ug/ml after 36 to 40 hr incubation by Giemsa staining	Plasmodium falciparum 3D7	100.0 %
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as inhibition of schizont maturation at 50 ug/ml after 36 to 40 hr incubation by Giemsa staining	Plasmodium falciparum 3D7	100.0 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2235159
PubChem	56946883

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).